Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Patent
1994-12-29
1998-08-04
Hutzell, Paula K.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
4241841, 4242771, 4241371, 424422, 424423, 4242831, 4242781, 4241941, 4242341, 4241411, 4241551, 4241561, 4241741, 5303875, 5303897, 530395, 530806, 530828, 5303877, 5303881, 514 42, 514 25, 514885, A61K 3900, A61K 4500
Patent
active
057889856
ABSTRACT:
The invention provides novel uses for n-glycolylated gangliosides, or derivatives and/or oligosaccharides thereof. The invention further provides methods of obtaining such gangliosides, as well as vaccine compositions comprising said gangliosides. The gangliosides may be coupled to carriers and may be accompanied by adjuvants. The vaccine compositions can be used in the treatment of breast cancers, whereby the gangliosides are used to elicit an immune response to corresponding gangliosides on breast tumour cells.
REFERENCES:
patent: 5026557 (1991-06-01), Estis et al.
patent: 5102663 (1992-04-01), Livingston et al.
Furukawa et. al. (1988) J. Biol. Chem. vol. 263 (34), 18507-18512 Analysis of the Expression of N-Glycolylneuraminic Acid.
Dohi et. al. (1988) Cancer. Res. vol. 48, 5680-5685 An IgG.sub.3 Monoclonal Antibody Established After Immunization.
Hamilton et. al. (1993) Int. J. Cancer vol. 53, 566-573 Gangliosid Expression on Human Malignant Melanoma.
Portoukalian et. al. (1991) Int. J. Cancer, vol. 49, 893-899 Humoral Immune Response in Disease-Free Advanced Melanoma.
Article entitled: G.sub.M2 -KLH Conjugate Vaccine: Increased Immunogenicity in Melanoma Patients After Administration With Immunological Adjuvant QS-21. Authors: Friedhelm Helling, Shengle Zhang, Ann Shang, Sucharita Adluri, Michele Calves, Rao Koganty, B. Michael Longenecker, Tzy-J. Yao, Herbert F. Oettgen, and Philip O. Livingston--Published in Cancer Research 55. 2783-2788, Jul. 1, 1995.
Article entitled: GD3/Proteosome Vaccines Induce Consistent IgM Antibodies against the Ganglioside GD3. Authors: Philip O. Livingston, Michele J. Calves, Friedhelm Helling, Wendell D. Zollinger, Milan S. Blake and George H. Lowell--Published in Vaccine, vol. 11, Issue 12, 1993.
Article entitled: Characterization of IgG and IgM Antibodies Induced in Melanoma Patients by Immunization with Purified G.sub.M2 Ganglioside. Authors: Philip O. Livingston, Gerd Ritter, Pramod Srivastava, Maureen Padavan, Michele J. Calves, Herbert F. Oettgen and Lloyd J. Old--Published in Cancer Research 49, 7045-7050, Dec. 15, 1989.
Article entitled: Humoral Immune Response in Disease-Free Advanced Melanoma Patients After Vaccination with Melanoma-Associated Gangliosides. Authors: Jacques Portoukalian, Stefan Carrel, Jean-Francois Dore and Philip Rumke, on behalf of the EORTC Cooperative Melanoma Group--Published in the International Journal of Cancer 49, 893-899 (1991).
Carr Pérez Adriana
Hernandez Oscar Gonzalo Valiente
Molina Luis Enrique Fernandez
Rodriguez Gilda Marquina
Rodriguez Rolando Perez
Centro de Inmunologia Molecular
Hutzell Paula K.
Masood Khalid
LandOfFree
Vaccine composition for eliciting an immune response against N-g does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine composition for eliciting an immune response against N-g, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine composition for eliciting an immune response against N-g will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1174430